Shawn M McClintock1, Robin B Dail, Laura S Howe-Martin, Tara K Mann, Donald E Bailey. 1. Author Affiliations: Division of Psychology, Department of Psychiatry, UT Southwestern Medical Center (Drs McClintock and Howe-Martin), Dallas, Texas; Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine (Dr McClintock), Durham, North Carolina; College of Nursing, University of South Carolina (Dr Dail), Columbia, South Carolina; Moncrief Cancer Institute, UT Southwestern Medical Center (Dr Howe-Martin); Duke Clinical Research Institute (Dr Mann), Durham, North Carolina; and Duke University School of Nursing (Dr Bailey), Durham, North Carolina.
Abstract
BACKGROUND: High-dose interleukin-2 is a therapy available for individuals with renal cell carcinoma; however, it can produce adverse effects, specifically depressive symptoms. There is limited information regarding the trajectory of depressive symptoms and measurement-based care assessment of depressive symptoms. OBJECTIVE: The purpose was to describe the trajectory of depressive symptoms and compare 2 depression measures. METHODS: A descriptive, mixed-method case study approach was used to describe the longitudinal trajectory of depressive symptoms The qualitative assessment included a journal entry and an interview. The quantitative depression symptom severity measures included the 8-item self-report Patient-Reported Outcomes Measurement Information System Depression and the 30-item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C). RESULTS: Ten cases were enrolled. The maximum number of interleukin-2 doses that any patient received within a single hospitalization ranged from 4 to 12. Mean scores on the 8-item Patient-Reported Outcomes Measurement Information System Depression showed no changes in depressive symptoms from pretreatment to posttreatment, nor across hospitalizations. Mean total scores on the IDS-C increased from "normal" to "mild severity" depressive symptom range across all treatment cycles, suggesting transient depressive symptoms within hospitalizations. Qualitative data from the case supported the IDS-C increase, suggesting that the patient developed depressive symptoms pretreatment to posttreatment. CONCLUSIONS: Understanding the trajectory of depressive symptoms allows for the identification of critical time points when depressive symptoms present and change across treatment. It is critical to use measurement-based care using validated measures to assess for the presence and changes in depressive symptoms. IMPLICATIONS FOR PRACTICE: Validated self-report or clinician-rated depression symptom measures should be used to document the presence or absence of depressive symptoms in this population.
BACKGROUND: High-dose interleukin-2 is a therapy available for individuals with renal cell carcinoma; however, it can produce adverse effects, specifically depressive symptoms. There is limited information regarding the trajectory of depressive symptoms and measurement-based care assessment of depressive symptoms. OBJECTIVE: The purpose was to describe the trajectory of depressive symptoms and compare 2 depression measures. METHODS: A descriptive, mixed-method case study approach was used to describe the longitudinal trajectory of depressive symptoms The qualitative assessment included a journal entry and an interview. The quantitative depression symptom severity measures included the 8-item self-report Patient-Reported Outcomes Measurement Information System Depression and the 30-item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C). RESULTS: Ten cases were enrolled. The maximum number of interleukin-2 doses that any patient received within a single hospitalization ranged from 4 to 12. Mean scores on the 8-item Patient-Reported Outcomes Measurement Information System Depression showed no changes in depressive symptoms from pretreatment to posttreatment, nor across hospitalizations. Mean total scores on the IDS-C increased from "normal" to "mild severity" depressive symptom range across all treatment cycles, suggesting transient depressive symptoms within hospitalizations. Qualitative data from the case supported the IDS-C increase, suggesting that the patient developed depressive symptoms pretreatment to posttreatment. CONCLUSIONS: Understanding the trajectory of depressive symptoms allows for the identification of critical time points when depressive symptoms present and change across treatment. It is critical to use measurement-based care using validated measures to assess for the presence and changes in depressive symptoms. IMPLICATIONS FOR PRACTICE: Validated self-report or clinician-rated depression symptom measures should be used to document the presence or absence of depressive symptoms in this population.
Authors: Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112
Authors: Kerrie Clover; Sylvie D Lambert; Christopher Oldmeadow; Benjamin Britton; Madeleine T King; Alex J Mitchell; Gregory Carter Journal: Qual Life Res Date: 2018-02-08 Impact factor: 4.147
Authors: H Ryan; P Schofield; J Cockburn; P Butow; M Tattersall; J Turner; A Girgis; D Bandaranayake; D Bowman Journal: Eur J Cancer Care (Engl) Date: 2005-03 Impact factor: 2.520
Authors: Rebecca M Saracino; Mark I Weinberger; Andrew J Roth; Arti Hurria; Christian J Nelson Journal: Psychooncology Date: 2016-05-16 Impact factor: 3.894
Authors: Roxanne Payne; Lyn Glenn; Helena Hoen; Beverley Richards; John W Smith; Robert Lufkin; Todd S Crocenzi; Walter J Urba; Brendan D Curti Journal: J Immunother Cancer Date: 2014-05-14 Impact factor: 13.751